Loading financial data...

Hepion Pharmaceuticals, Inc. (CTRVP) Financial Statements | Global Financial Data

Hepion Pharmaceuticals, Inc.

CTRVPSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1583771

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	$0.00	$0.00	$0.00
Research and Development Expense	$11.8M	$35.6M	$33.3M	$20.4M	$12.0M
Operating Expenses	$19.3M	$48.4M	$45.5M	$30.4M	$20.1M
Operating Income (Loss)	-$19.3M	-$48.4M	-$45.5M	-$30.4M	-$20.1M
Interest Expense	—	—	$10.2K	$8.9K	$31.2K
Nonoperating Income (Expense)	—	—	—	—	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$16.2M	-$49.3M	-$45.1M	-$32.7M	-$20.3M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$1.6M	$18.1M	$60.2M	$103.6M	$48.6M
Assets, Current	$1.6M	$17.5M	$56.5M	$97.5M	$42.6M
Cash and Cash Equivalents, at Carrying Value	—	—	—	—	—
Liabilities	$3.5M	$10.8M	$10.4M	$10.6M	$8.1M
Liabilities, Current	$3.1M	$5.3M	$7.9M	$8.2M	$4.7M
Accounts Payable, Current	$220.2K	$2.3M	$2.7M	$2.4M	$3.7M
Stockholders' Equity Attributable to Parent	$7.3M	$49.9M	$93.0M	$40.5M	$15.6M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$18.2M	-$40.9M	-$35.0M	-$31.2M	-$16.2M
Net Cash Provided by (Used in) Investing Activities	-$600.0K	-$14.3K	-$14.1K	-$130.4K	-$85.8K
Net Cash Provided by (Used in) Financing Activities	$4.3M	$4.5M	-$5.1M	$82.0M	$43.1M
Payments to Acquire Property, Plant, and Equipment	—	$14.3K	$16.3K	$130.4K	$88.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)